EP 1843777 A2 20071017 - HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION
Title (en)
HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION
Title (de)
HIV-1-GP41-FUSIONSPEPTIDE ZUR IMMUNMODULATION
Title (fr)
PEPTIDES DE FUSION VIH-1 GP41 POUR UNE IMMUNOMODULATION
Publication
Application
Priority
- IL 2006000096 W 20060124
- US 64560505 P 20050124
Abstract (en)
[origin: WO2006077601A2] The present invention provides pharmaceutical compositions and methods for prevention or treatment of autoimmune diseases and other T cell mediated inflammatory diseases and conditions, which comprise as an active ingredient an effective quantity of a peptide derived from HIV gp41 fusion peptide domain or fragments, analogs, homologs and derivatives thereof. The invention further provides novel peptides derived from HIV gp41 fusion peptide domain, useful in the treatment of T cell mediated pathologies.
IPC 8 full level
A61K 38/00 (2006.01)
CPC (source: EP US)
A61K 38/162 (2013.01 - EP US); A61P 1/02 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 14/005 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US); C12N 2740/16122 (2013.01 - EP US)
Citation (search report)
See references of WO 2006077601A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2006077601 A2 20060727; WO 2006077601 A3 20061123; AU 2006207181 A1 20060727; CA 2595414 A1 20060727; CN 101115498 A 20080130; EP 1843777 A2 20071017; JP 2008528480 A 20080731; US 2009270312 A1 20091029
DOCDB simple family (application)
IL 2006000096 W 20060124; AU 2006207181 A 20060124; CA 2595414 A 20060124; CN 200680002209 A 20060124; EP 06701338 A 20060124; JP 2007551814 A 20060124; US 72206406 A 20060124